BXRX News and Press, Baudax Bio Inc. From 07/01/23

2023-07-01 11:16:00 ET 3 Tips for Analyzing Penny Stocks Charts Like a Pro Navigating the world of penny stocks—those enticing equities trading at less than $5 per share—can be a rewarding yet complex endeavor. The high volatility that characterizes these assets offers uni...

2023-06-30 10:56:09 ET Baudax Bio ( NASDAQ: BXRX ) said on Friday that it had acquired TeraImmune, a Treg research company BXRX shares more than double, up +163.4% . Under the deal, TeraImmune's outstanding equity interests were exchanged for a combination of...

TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of Combined Entity MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) --  Baudax Bio, In...

MALVERN, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, today announced additional results from its Phase 2 clinical trial of BX1000 for neuromuscular...

MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, recently announced that it has adjourned its Annual Meeting of Shareholders (the “Annua...

2023-05-12 11:33:37 ET Baudax Bio press release ( NASDAQ: BXRX ): Q1 GAAP EPS of -$3.91. As of March 31, 2023, Baudax Bio had cash and cash equivalents of $3.8 million. For further details see: Baudax Bio GAAP EPS of -$3.91

Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent Portfolio Secured $4 Million in Gross Proceeds from Public Offering in May MALVERN...

MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, w...

MALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related settings, today announced the closing of its previously announced public off...

2023-04-27 12:24:19 ET Gainers: TOP Financial Group Limited ( TOP ) +186% . Evelo Biosciences ( EVLO ) +184% . ContraFect Corporation ( CFRX ) +68% . U Power Limited Ordinary Shares ( UCAR ) +40% . Atomera Incorporated ( ATOM ) +33...